{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:04:05Z","timestamp":1791993845333,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001414"],"award-info":[{"award-number":["UL1 TR001414"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Marburg virus (MARV) is a member of the filovirus family that causes hemorrhagic disease with high case fatality rates. MARV is on the priority list of the World Health Organization for countermeasure development highlighting its potential impact on global public health. We developed a vesicular stomatitis virus (VSV)-based vaccine expressing the MARV glycoprotein (VSV-MARV) and previously demonstrated uniform protection of nonhuman primates (NHPs) with a single dose. Here, we investigated the fast-acting potential of this vaccine by challenging NHPs with MARV 14, 7 or 3 days after a single dose vaccination with VSV-MARV. We found that 100% of the animals survived when vaccinated 7 or 14 days and 75% of the animal survived when vaccinated 3 days prior to lethal MARV challenge. Transcriptional analysis of whole blood samples indicated activation of B cells and antiviral defense after VSV-MARV vaccination. In the day -14 and -7 groups, limited transcriptional changes after challenge were observed with the exception of day 9 post-challenge in the day -7 group where we detected gene expression profiles indicative of a recall response. In the day -3 group, transcriptional analysis of samples from surviving NHPs revealed strong innate immune activation. In contrast, the animal that succumbed to disease in this group lacked signatures of antiviral immunity. In summary, our data demonstrate that the VSV-MARV is a fast-acting vaccine suitable for the use in emergency situations like disease outbreaks in Africa.<\/jats:p>","DOI":"10.3389\/fimmu.2021.774026","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:03:09Z","timestamp":1635314589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Andrea","family":"Marzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Jankeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Menicucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Callison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle L.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Pinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/82_2017_8","article-title":"Filovirus Research: How It Began","volume":"411","author":"Slenczka","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00095-19","article-title":"A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967","volume":"84","author":"Ristanovic","year":"2020","journal-title":"Microbiol Mol Biol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1086\/520551","article-title":"Forty Years of Marburg Virus","volume":"196","author":"Slenczka","year":"2007","journal-title":"J Infect Dis"},{"key":"B4","article-title":"Marburg and Ebola Viruses","volume-title":"Fields Virology","author":"Feldmann","year":"2013"},{"key":"B5","volume-title":"Prioritizing Diseases for Research and Development in Emergency Contexts","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg Virus Vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258","article-title":"Live Attenuated Recombinant Vaccine Protects Nonhuman Primates Against Ebola and Marburg Viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation","volume":"9","author":"Marzi","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure Protection Against Marburg Haemorrhagic Fever With Recombinant Vesicular Stomatitis Virus Vectors in Non-Human Primates: An Efficacy Assessment","volume":"367","author":"Daddario-DiCaprio","year":"2006","journal-title":"Lancet"},{"key":"B10","volume-title":"First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response","year":"2019"},{"key":"B11","volume-title":"First Vaccine to Protect Against Ebola","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV Rapidly Protects Macaques Against Infection With the 2014\/15 Ebola Virus Outbreak Strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results From the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ca Suffit)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single Low-Dose VSV-EBOV Vaccination Protects Cynomolgus Macaques From Lethal Ebola Challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies Are Necessary for rVSV\/ZEBOV-GP-Mediated Protection Against Lethal Ebola Virus Challenge in Nonhuman Primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv095","article-title":"Immune Response to Marburg Virus Angola Infection in Nonhuman Primates","volume":"212","author":"Fernando","year":"2015","journal-title":"J Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39214","DOI":"10.1038\/srep39214","article-title":"A Hamster Model for Marburg Virus Infection Accurately Recapitulates Marburg Hemorrhagic Fever","volume":"6","author":"Marzi","year":"2016","journal-title":"Sci Rep"},{"key":"B18","article-title":"A Simple Method of Estimating Fifty Per Cent Endpoints","volume":"27","author":"Muench","year":"1938","journal-title":"Amerivan J Hyg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0937","article-title":"Gamma Irradiation as an Effective Method for Inactivation of Emerging Viral Pathogens","volume":"100","author":"Feldmann","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12859-016-1241-0","article-title":"Systempiper: NGS Workflow and Report Generation Environment","volume":"17","author":"Backman","year":"2016","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"Edger: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu333","article-title":"Next Masigpro: Updating Masigpro Bioconductor Package for RNA-Seq Time Series","volume":"30","author":"Nueda","year":"2014","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.11.002","article-title":"Chanda, Meta- and Orthogonal Integration of Influenza \u201cOMICs\u201d Data Defines a Role for UBR4 in Virus Budding","volume":"18","author":"Tripathi","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates","volume":"9","author":"Mire","year":"2014","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4201","article-title":"Human Antibody Repertoire After VSV-Ebola Vaccination Identifies Novel Targets and Virus-Neutralizing IgM Antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.042","article-title":"Systematic Review of Marburg Virus Vaccine Nonhuman Primate Studies and Human Clinical Trials","volume":"39","author":"Dulin","year":"2021","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6128","article-title":"Ebola Vaccine-Induced Protection in Nonhuman Primates Correlates With Antibody Specificity and Fc-Mediated Effects","volume":"13","author":"Meyer","year":"2021","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00597-19","article-title":"Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection","volume":"10","author":"Menicucci","year":"2019","journal-title":"mBio"},{"key":"B29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic Analysis Reveals a Previously Unknown Role for CD8(+) T-Cells in rVSV-EBOV Mediated Protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00733-14","article-title":"Next-Generation Sequencing Reveals a Controlled Immune Response to Zaire Ebola Virus Challenge in Cynomolgus Macaques Immunized With Vesicular Stomatitis Virus Expressing Zaire Ebola Virus Glycoprotein (VSVDeltaG\/EBOVgp)","volume":"22","author":"Barrenas","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020067","article-title":"Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine","volume":"9","author":"Santoro","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection","volume":"212","author":"Geisbert","year":"2015","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/v10110658","article-title":"Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis","volume":"10","author":"Blair","year":"2018","journal-title":"Viruses"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1086\/652748","article-title":"Factors Associated With Marburg Hemorrhagic Fever: Analysis of Patient Data From Uige, Angola","volume":"201","author":"Roddy","year":"2010","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.12.023","article-title":"Viral Load Among Patients Infected With Marburgvirus in Angola","volume":"39","author":"Weidmann","year":"2007","journal-title":"J Clin Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"158128","DOI":"10.1155\/2014\/158128","article-title":"The Early Activation of CD8+ T Cells Is Dependent on Type I IFN Signaling Following Intramuscular Vaccination of Adenovirus Vector","volume":"2014","author":"Hemmi","year":"2014","journal-title":"BioMed Res Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/520608","article-title":"Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment With Recombinant Nematode Anticoagulant Protein C2","volume":"196","author":"Geisbert","year":"2007","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0009300","DOI":"10.1371\/journal.pntd.0009300","article-title":"Early Control of Viral Load by Favipiravir Promotes Survival to Ebola Virus Challenge and Prevents Cytokine Storm in Non-Human Primates","volume":"15","author":"Reynard","year":"2021","journal-title":"PloS Negl Trop Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3201\/eid2110.150259","article-title":"Delayed Disease Progression in Cynomolgus Macaques Infected With Ebola Virus Makona Strain","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0252874","DOI":"10.1371\/journal.pone.0252874","article-title":"Natural History of Disease in Cynomolgus Monkeys Exposed to Ebola Virus Kikwit Strain Demonstrates the Reliability of This Non-Human Primate Model for Ebola Virus Disease","volume":"16","author":"Niemuth","year":"2021","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"n1988","DOI":"10.1136\/bmj.n1988","article-title":"Guinea Reports West Africa\u2019s First Ever Case of Marburg Virus Disease","volume":"374","author":"Mahase","year":"2021","journal-title":"BMJ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.774026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:03:16Z","timestamp":1635314596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.774026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2021.774026"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.774026","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"774026"}}